Jump to main content
Jump to site search

Issue 11, 2013
Previous Article Next Article

Small-molecule inhibitors of SREBP activation – potential for new treatment of metabolic disorders

Author affiliations

Abstract

Sterol regulatory element-binding proteins (SREBPs) are transcriptional factors that control lipid and cholesterol metabolism. Activation of SREBPs in response to a decrease in cellular sterols results in acceleration of the synthesis of fatty acids, triglycerides, and cholesterol. Aberrant SREBP activity has been linked to metabolic disease states, such as obesity, fatty liver, insulin resistance, hyperlipidemia, and atherosclerosis. Thus, inhibition of SREBP activation is a potential therapeutic approach to treating metabolic disorders. This review focuses on direct or indirect small-molecule inhibitors of SREBP activation.

Graphical abstract: Small-molecule inhibitors of SREBP activation – potential for new treatment of metabolic disorders

Back to tab navigation

Article information


Submitted
20 Jun 2013
Accepted
15 Aug 2013
First published
19 Aug 2013

Med. Chem. Commun., 2013,4, 1422-1433
Article type
Review Article

Small-molecule inhibitors of SREBP activation – potential for new treatment of metabolic disorders

M. Watanabe and M. Uesugi, Med. Chem. Commun., 2013, 4, 1422
DOI: 10.1039/C3MD00177F

Search articles by author

Spotlight

Advertisements